Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice

Vaccine

Volumn 36, Issue 22, 2018, Pages 3090-3100

  Lehrer, Axel T ^a,d   Wong, Teri Ann S ^a,d   Lieberman, Michael M ^b,d   Humphreys, Tom ^b   Clements, David E ^b   Bakken, Russell R ^c   Hart, Mary Kate ^c,e   Pratt, William D ^c   Dye, John M ^c  

^a PanThera Biopharma LLC   (United States)

^b HAWAII BIOTECH INC   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e DynPort Vaccine Company   (United States)

Author keywords

GP; Recombinant subunit proteins; Subunit vaccine; VP24; VP40; Zaire ebolavirus

Indexed keywords

COVACCINE HT; EBOLA VACCINE; GAMMA INTERFERON; GPI 0100; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MATRIX PROTEIN; MONTANIDE ISA 51; PROTEIN VP40; RECOMBINANT PROTEIN; RIBI R 700; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VP24 PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VP24 PROTEIN, EBOLA VIRUS; VP40 PROTEIN, VIRUS;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FEMALE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROOF OF CONCEPT; S2 CELL LINE; SPLEEN CELL; ZAIRE EBOLAVIRUS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELLULAR IMMUNITY; EBOLAVIRUS; HUMORAL IMMUNITY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 85012922355     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.01.068     Document Type: Article

References (54)

1. Henao-Restrepo, A.M., Camacho, A., Longini, I.M., Watson, C.H., Edmunds, W.J., Egger, M., et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet, 2016.
2. Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N.E., Edmunds, W.J., Camacho, A., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:9996 (2015), 857–866.
3. Huttner, A., Dayer, J.A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15:10 (2015), 1156–1166.
4. Ksiazek, T.G., Rollin, P.E., Williams, A.J., Bressler, D.S., Martin, M.L., Swanepoel, R., et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179:Suppl 1 (1999), S177–S187.
5. Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179:Suppl 1 (1999), S18–S23.
6. Qiu, X., Audet, J., Wong, G., Fernando, L., Bello, A., Pillet, S., et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep, 3, 2013, 3365.
7. Khurana, S., Fuentes, S., Coyle, E.M., Ravichandran, S., Davey, R.T. Jr., Beigel, J.H., Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med 22:12 (2016), 1439–1447.
8. Noda, T., Sagara, H., Suzuki, E., Takada, A., Kida, H., Kawaoka, Y., Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76:10 (2002), 4855–4865.
9. Takada, A., Ebihara, H., Jones, S., Feldmann, H., Kawaoka, Y., Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25:6 (2007), 993–999.
10. Jones, S.M., Feldmann, H., Stroher, U., Geisbert, J.B., Fernando, L., Grolla, A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:7 (2005), 786–790.
11. Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., Xu, L., Yang, Z.Y., Roederer, M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:6949 (2003), 681–684.
12. Herbert, A.S., Kuehne, A.I., Barth, J.F., Ortiz, R.A., Nichols, D.K., Zak, S.E., et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87:9 (2013), 4952–4964.
13. Bukreyev, A., Rollin, P.E., Tate, M.K., Yang, L., Zaki, S.R., Shieh, W.J., et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81:12 (2007), 6379–6388.
14. Marzi, A., Ebihara, H., Callison, J., Groseth, A., Williams, K.J., Geisbert, T.W., et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204:Suppl 3 (2011), S1066–S1074.
15. Xu, L., Sanchez, A., Yang, Z., Zaki, S.R., Nabel, E.G., Nichol, S.T., et al. Immunization for Ebola virus infection. Nat Med 4:1 (1998), 37–42.
16. Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y., Nabel, G.J., Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:6812 (2000), 605–609.
17. Warfield, K.L., Posten, N.A., Swenson, D.L., Olinger, G.G., Esposito, D., Gillette, W.K., et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 196:Suppl 2 (2007), S421–S429.
18. Simmons, G., Lee, A., Rennekamp, A.J., Fan, X., Bates, P., Shen, H., Identification of murine T-cell epitopes in Ebola virus nucleoprotein. Virology 318:1 (2004), 224–230.
19. Wilson, J.A., Hart, M.K., Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 75:6 (2001), 2660–2664.
20. Wilson, J.A., Bray, M., Bakken, R., Hart, M.K., Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286:2 (2001), 384–390.
21. Olinger, G.G., Bailey, M.A., Dye, J.M., Bakken, R., Kuehne, A., Kondig, J., et al. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 79:22 (2005), 14189–14196.
22. Warfield, K.L., Swenson, D.L., Olinger, G.G., Kalina, W.V., Aman, M.J., Bavari, S., Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196:Suppl 2 (2007), S430–S437.
23. Ignatyev, G.M., Agafonov, A.P., Streltsova, M.A., Kashentseva, E.A., Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol 44:1–3 (1996), 111–118.
24. Geisbert, T.W., Pushko, P., Anderson, K., Smith, J., Davis, K.J., Jahrling, P.B., Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8:5 (2002), 503–507.
25. Modis, Y., Ogata, S., Clements, D., Harrison, S.C., A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100:12 (2003), 6986–6991.
26. Modis, Y., Ogata, S., Clements, D., Harrison, S.C., Structure of the dengue virus envelope protein after membrane fusion. Nature 427:6972 (2004), 313–319.
27. Marciani, D.J., Press, J.B., Reynolds, R.C., Pathak, A.K., Pathak, V., Gundy, L.E., et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18:27 (2000), 3141–3151.
28. Marciani, D.J., Reynolds, R.C., Pathak, A.K., Finley-Woodman, K., May, R.D., Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21:25–26 (2003), 3961–3971.
29. Hilgers, L.A., Blom, A.G., Sucrose fatty acid sulphate esters as novel vaccine adjuvant. Vaccine, 2006, 24 (Suppl 2) S2-81-2.
30. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., Huggins, J., A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178:3 (1998), 651–661.
31. Ksiazek, T.G., West, C.P., Rollin, P.E., Jahrling, P.B., Peters, C.J., ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 179:Suppl 1 (1999), S192–S198.
32. Timmins, J., Schoehn, G., Ricard-Blum, S., Scianimanico, S., Vernet, T., Ruigrok, R.W., et al. Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J Mol Biol 326:2 (2003), 493–502.
33. Mellquist-Riemenschneider, J.L., Garrison, A.R., Geisbert, J.B., Saikh, K.U., Heidebrink, K.D., Jahrling, P.B., et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 92:2 (2003), 187–193.
34. Konduru, K., Bradfute, S.B., Jacques, J., Manangeeswaran, M., Nakamura, S., Morshed, S., et al. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 29:16 (2011), 2968–2977.
35. Phoolcharoen, W., Bhoo, S.H., Lai, H., Ma, J., Arntzen, C.J., Chen, Q., et al. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J 9:7 (2011), 807–816.
36. Hevey, M., Negley, D., Geisbert, J., Jahrling, P., Schmaljohn, A., Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239:1 (1997), 206–216.
37. Hevey, M., Negley, D., VanderZanden, L., Tammariello, R.F., Geisbert, J., Schmaljohn, C., et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20:3–4 (2001), 586–593.
38. Phoolcharoen, W., Dye, J.M., Kilbourne, J., Piensook, K., Pratt, W.D., Arntzen, C.J., et al. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci U S A 108:51 (2011), 20695–20700.
39. Bosio, C.M., Moore, B.D., Warfield, K.L., Ruthel, G., Mohamadzadeh, M., Aman, M.J., et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 326:2 (2004), 280–287.
40. Ye, L., Lin, J., Sun, Y., Bennouna, S., Lo, M., Wu, Q., et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351:2 (2006), 260–270.
41. Warfield, K.L., Bosio, C.M., Welcher, B.C., Deal, E.M., Mohamadzadeh, M., Schmaljohn, A., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 100:26 (2003), 15889–15894.
42. Geisbert, T.W., Jahrling, P.B., Exotic emerging viral diseases: progress and challenges. Nat Med 10:12 Suppl (2004), S110–S121.
43. Falasca, L., Agrati, C., Petrosillo, N., Di Caro, A., Capobianchi, M.R., Ippolito, G., et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ 22:8 (2015), 1250–1259.
44. Bosio, C.M., Aman, M.J., Grogan, C., Hogan, R., Ruthel, G., Negley, D., et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188:11 (2003), 1630–1638.
45. Stroher, U., West, E., Bugany, H., Klenk, H.D., Schnittler, H.J., Feldmann, H., Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75:22 (2001), 11025–11033.
46. Escudero-Perez, B., Volchkova, V.A., Dolnik, O., Lawrence, P., Volchkov, V.E., Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog, 10(11), 2014, e1004509.
47. Yaddanapudi, K., Palacios, G., Towner, J.S., Chen, I., Sariol, C.A., Nichol, S.T., et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 20:14 (2006), 2519–2530.
48. Basler, C.F., Mikulasova, A., Martinez-Sobrido, L., Paragas, J., Muhlberger, E., Bray, M., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77:14 (2003), 7945–7956.
49. Basler, C.F., Wang, X., Muhlberger, E., Volchkov, V., Paragas, J., Klenk, H.D., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97:22 (2000), 12289–12294.
50. Reid, S.P., Valmas, C., Martinez, O., Sanchez, F.M., Basler, C.F., Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 81:24 (2007), 13469–13477.
51. Reid, S.P., Leung, L.W., Hartman, A.L., Martinez, O., Shaw, M.L., Carbonnelle, C., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80:11 (2006), 5156–5167.
52. Bray, M., The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 82:Pt 6 (2001), 1365–1373.
53. Ebihara, H., Takada, A., Kobasa, D., Jones, S., Neumann, G., Theriault, S., et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog, 2(7), 2006, e73.
54. Kash, J.C., Muhlberger, E., Carter, V., Grosch, M., Perwitasari, O., Proll, S.C., et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 80:6 (2006), 3009–3020.